Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Optimizing CRC and uHCC outcomes with TKIs

Michel Ducreux • 28 Sep 2019
ESMO 2019
Colorectal Cancer Gastrointestinal Cancer Liver Cancer Regorafenib Sorafenib

Michel Ducreux, MD, PhD, Gustave Roussy Institute, Villejuif, France, discusses whether TKIs have the potential to optimize outcomes in refractory metastatic colorectal cancer (mCRC) and unresectable hepatocellular carcinoma (uHCC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Michel Ducreux

1:40
Early diagnosis in advanced pancreatic cancer: how will we achieve this?
Michel Ducreux • 1 Oct 2019
1:48
Pancreatic cancer: moving forward
Michel Ducreux • 1 Oct 2019
1:31
Pancreatic Cancer: peri-operative precision
Michel Ducreux • 29 Sep 2019
2:04
Synergy of anti-androgenic agents and immune checkpoint inhibitors in HCC
Michel Ducreux • 9 Nov 2018

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals